Pcn235 - Combination Oncology Therapies in the Eu5: Navigating the Road to Reimbursement and Optimizing Uptake in Malignant Melanoma

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.317
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Time to Reimbursement for Oncology Drugs in EU5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd92 - Access and Reimbursement for Current and Emerging Alzheimer’s Disease-Modifying Therapies in the Eu5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Navigating the Road to Europe

English

Pcn283 - Identifying the Key Challenges Affecting the Reimbursement of Car-T Therapies in the Eu5 Using a Web-Based Portal to Engage Payers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cohort Versus Patient Level Simulation for the Economic Evaluation of Single Versus Combination Immuno-Oncology Therapies in Metastatic Melanoma

Journal of Medical Economics
Health Policy
2019English

Psy137 - Orphan Drug Access and Reimbursement in the Eu5: Cystic Fibrosis and Duchenne Muscular Dystrophy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We Are Not Done Yet

Frontiers in Oncology
Cancer ResearchOncology
2015English

Barriers to Oncology Biosimilars Uptake in the United States

Oncologist
Cancer ResearchMedicineOncology
2018English

Stem Cells in Cardiovascular Medicine: The Road to Regenerative Therapies

Current Cardiology Reports
Cardiovascular MedicineCardiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy